Important update for Louisiana individuals affected by recalled ranitidine products.
Why Zantac Was Removed From the Market
For decades, Zantac and its generic ranitidine products were used to treat heartburn, GERD, and stomach ulcers. In 2019, independent testing revealed that ranitidine could break down into N-Nitrosodimethylamine (NDMA): a chemical the FDA and EPA classify as a probable human carcinogen.
Key Findings That Led to the Recall
- NDMA levels in ranitidine can increase over time
- Heat and improper storage may accelerate NDMA formation
- Some samples contained hundreds of times the acceptable limit of NDMA
- The FDA ultimately requested that all ranitidine products be removed from U.S. shelves
Patients who relied on Zantac were not warned of these risks, and thousands of individuals nationwide began pursuing legal action against drug manufacturers.


